Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Immuneering announced a clinical trial supply agreement with Regeneron Pharmaceuticals for its anti-PD-1 therapy, Libtayo. The agreement supports the evaluation of IMM-1-104, in combination with ...

(MENAFN- GlobeNewsWire - Nasdaq) - Progression-free survival data from more than 30 patients ... with Regeneron Pharmaceuticals to evaluate IMM-1-104 in combination with Libtayo® (cemiplimab ...

Yancopoulos, M.D., Ph.D., expressed optimism about the potential of these treatments, including Libtayo ... issues with patient co-pay assistance programs. Cantor Fitzgerald’s analyst, Carter Gould, ...

Regeneron aims to advance cancer treatments through innovative research and partnerships while emphasizing the significance of their PD-1 inhibitor, Libtayo, in ongoing clinical trials.

Regeneron continues to deliver growth on top/bottom line in the near to longer-term with Dupi and Libtayo, the analyst tells investors in a research note.

Yancopoulos, M.D., Ph.D., Board co-Chair, President and Chief Scientific Officer at Regeneron. “Our PD-1 inhibitor Libtayo is the standard of care in advanced cutaneous squamous cell carcinoma ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Q1 2025 Earnings Call Transcript April 29, 2025 Regeneron Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $8.22 EPS ...

Q1 earnings and revenue miss expectations, mainly due to falling EYLEA sales. Stock rises on optimism around new drug approvals, pipeline progress, and upcoming FDA decisions. Don’t miss this ...

The U.S. Senate on Tuesday confirmed Fertitta to be ambassador to Italy. Credit: Mark Felix for The Texas Tribune Audio recording is automated for accessibility. Humans wrote and edited the story.